Aberrant serum polyunsaturated fatty acids profile is relevant with acute coronary syndrome.
Aberrant serum polyunsaturated fatty acids profile is relevant with acute coronary syndrome.
复制标题
异常的血清多不饱和脂肪酸谱与急性冠脉综合征相关。
DOI：
10.1007/s00380-015-0721-x
复制
发表时间：
2016
期刊：
影响因子：
1.5
通讯作者：
Hayashi H.
中科院分区：
文献类型：
--
作者：
Sakamoto A;Saotome M;Hosoya N;Kageyama S;Yoshizaki T;Takeuchi R;Murata K;Nawada R;Onodera T;Takizawa A;Satoh H;Hayashi H.
尽管已报道了异常血清多不饱和脂肪酸（PUFAs）谱与冠状动脉疾病（CAD）之间的稳健关系，但关于异常PUFAs谱与CAD临床特征之间的相关性的细节尚未完全发现。因此，我们研究了冠心病患者血清PUFAs与临床特征之间的关系。我们将595例接受冠状动脉造影的冠心病患者根据其临床特征分为3组（A组：早期ACS，n= 96; B组：稳定型CAD伴既往ACS病史，n= 259; C组：无ACS既往史的稳定CAD，n= 240）和测量的血清n-3 [二十碳五烯酸（EPA），二十二碳六烯酸（DHA）]和n-6 [花生四烯酸（AA）] PUFA。血清EPA、DHA和EPA/AA比值按A < B < C的顺序显著降低[EPA; 48.1（34.1-60.3）μg/ml，61.7（41.2-94.5）μg/ml，74.4（52.7-104.9）μg/ml，DHA; 113.1（92.8-135.1）μg/ml，125.8（100.4-167.2）μg/ml和140.1（114.7-177.0）μg/ml，EPA/AA比值; 0.31（0.22-0.45）、0.39（0.26-0.62）和0.44（0.31-0.69），四分位距中位数，p< 0.01]。多元回归分析显示，EPA（p= 0.009）和EPA/AA比值（p= 0.023），而不是DHA和DHA/AA比值，与CAD患者ACS的临床特征呈负相关。PUFAs谱与冠状动脉狭窄程度之间未观察到显著相关性。无论冠状动脉狭窄的程度和严重程度如何，低血清EPA和EPA/AA比值与CAD患者ACS的临床特征相关。
Although a robust relationship between aberrant serum polyunsaturated fatty acids (PUFAs) profile and coronary artery disease (CAD) has been reported, the details concerning the association between aberrant PUFAs profile and clinical feature of CAD are not fully discovered. Therefore, we investigated the relationship between serum PUFAs and clinical profiles in CAD patients. We classified 595 consecutive CAD patients, who underwent coronary angiography into 3 groups according to the clinical profiles of CAD (group A: early phase ACS,n= 96; group B: stable CAD with previous history of ACS,n= 259; group C: stable CAD without previous history of ACS,n= 240) and measured serumn-3 [eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)] andn-6 [arachidonic acid (AA)] PUFAs. Serum EPA, DHA, and EPA/AA ratio were significantly low in the order of group A < B < C [EPA; 48.1 (34.1–60.3) μg/ml, 61.7 (41.2–94.5) μg/ml, and 74.4 (52.7–104.9) μg/ml, DHA; 113.1 (92.8–135.1) μg/ml, 125.8 (100.4–167.2) μg/ml, and 140.1 (114.7–177.0) μg/ml, EPA/AA ratio; 0.31 (0.22–0.45), 0.39 (0.26–0.62), and 0.44 (0.31–0.69), medians with interquartile range,p< 0.01]. Multiple regression analysis revealed that EPA (p= 0.009) and EPA/AA ratio (p= 0.023), but not DHA and DHA/AA ratio, were negatively associated with clinical profiles of ACS in CAD patients. Significant correlation was not observed between PUFAs profile and severity of coronary stenosis. Low serum EPA and EPA/AA ratio correlates with clinical profiles of ACS in patients with CAD, regardless of the extent and severity of coronary artery stenosis.